SOURCE: YaFarm Technologies, Inc.
PITTSTON, ME--(Marketwire - Feb 11, 2013) - YaFarm Technologies, Inc. (PINKSHEETS: YFRM) (YaFarm, or the Company) announced today the appointment of top level management for the Integrative Stem Cell Institute (ISCI), a premier provider of point-of-care, stem cell-based therapies. YaFarm announced that David Audley has been appointed CEO of the ISCI, while Juan A. Castillo has been elected Chairman of the Board of Directors. YaFarm expects to announce members of its Board of Directors and Advisory Board in the near future.
Dr. Castillo, originally from Spain, has practiced medicine in Miami as an OB-GYN physician and laser surgeon for over three decades. Recognizing that many of the important needs and debilitating conditions of naturally aging women are not addressed in the traditional practice of medicine, he developed the Integrative Stem Cell Institute to provide cellular medical services to enhance, improve, and restore those needs and chronic conditions associated with aging. Dr. Castillo chose to place his institute in the Hospital Galenia because of its reputation for tremendous patient care and its staff of internationally recognized medical experts. Dr. Castillo is a pioneer in regenerative medicine and has successfully treated over 250 patients using adult stem cells. Dr. Castillo has been elected to the chairmanship of the board of directors for the ISCI where he will provide strategic vision and oversight.
David Audley has been appointed CEO of the ISCI. As CEO, Mr. Audley will oversee the day-to-day management of the ISCI, as well as its facilities in Cancun. Mr. Audley comes to the ISCI after successfully managing the International Cellular Medicine Society (ICMS) for nearly 4 years. As the founding executive director and CEO of the ICMS, Mr. Audley grew the organization from 7 physicians to over 3500 members from 35 countries. Under his leadership, the ICMS built the first registry of patient outcomes from stem cell treatments, published comprehensive guidelines and standards for the practice of cell-based medicine and developed a global program to evaluate laboratories and facilities involved in regenerative medicine. Mr. Audley also provided the leadership that resulted in the alliance between the ICMS and the AABB to combine the standards of the ICMS with the accreditation program and expertise of the AABB. Mr. Audley is a noted expert in field of regenerative medicine and has spoken extensively on global trends and perspectives.
Brian Hermenze, CEO of YaFarm Technologies, said, "Dr. Castillo and Mr. Audley will provide the executive leadership to take the post-merger ISCI to the next level. As a result of their affiliation, we were able to announce last week that we concluded a definitive agreement with the Hospital Galenia to provide stem cell treatments at the medical center." Mr. Hermenze continued, "The combination of Dr. Castillo's medical expertise and Mr. Audley's experience in the field is as good as it gets. Together, they will redefine the standard for care in regenerative medicine. I am excited about the potential for the ISCI under their leadership."
About Integrative Stem Cell Institute (ISCI)
The Integrative Stem Cell Institute (ISCI) is a premier provider of point-of-care, stem cell-based therapies for patients from around the world. With a state of the art laboratory housed within the Hospital Galenia in Cancun, Mexico, the ISCI combines the most advanced scientific application of stem cells with second to none medical care within the structure of adaptive clinical trials to effective track long term outcomes and assure patient safety. More information on the Integrative Stem Cell Institute is available at www.iscelli.com
SAFE HARBOR STATEMENT
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition, adequate financing, and other material risks. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance, or achievements to be materially different from the statements made herein.